CN104161748A - Application of rheum lhasaense extract A and B in preparation of biological preparation for reducing blood fat - Google Patents

Application of rheum lhasaense extract A and B in preparation of biological preparation for reducing blood fat Download PDF

Info

Publication number
CN104161748A
CN104161748A CN201310182203.2A CN201310182203A CN104161748A CN 104161748 A CN104161748 A CN 104161748A CN 201310182203 A CN201310182203 A CN 201310182203A CN 104161748 A CN104161748 A CN 104161748A
Authority
CN
China
Prior art keywords
preparation
lhasa rhubarb
extract
blood fat
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201310182203.2A
Other languages
Chinese (zh)
Inventor
胡琳
胡群
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KUNMING XIANGHAO SCIENCE AND TECHNOLOGY Co Ltd
Original Assignee
KUNMING XIANGHAO SCIENCE AND TECHNOLOGY Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KUNMING XIANGHAO SCIENCE AND TECHNOLOGY Co Ltd filed Critical KUNMING XIANGHAO SCIENCE AND TECHNOLOGY Co Ltd
Priority to CN201310182203.2A priority Critical patent/CN104161748A/en
Publication of CN104161748A publication Critical patent/CN104161748A/en
Pending legal-status Critical Current

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention discloses the chemical structural formulas of rheum lhasaense extract A and B, and an application of the rheum lhasaense extract A and B in the preparation of biological preparation for reducing blood fat. The two compounds have a prominent effect on reducing blood fat. Moreover the rheum lhasaense extract B may have a certain effect on treating fatty liver, and has a wide application in preparation of drugs for preventing and treating hyperlipidemia.

Description

Lhasa rhubarb element A, B are in the application of preparing in fat biological preparation
Technical field
The invention belongs to biomedicine field, relate to the medical usage of two novel resveratrol trimerizing compound Lhasa rhubarb element A and Lhasa rhubarb element B.
Background technology
Hyperlipemia mainly refers to serum total cholesterol (TC) or triglyceride (TG) level is too high and (or) Serum High-Density Lipoprotein-Cholesterol (HDL-C) level is too low.Hyperlipemia is person in middle and old age's commonly encountered diseases and frequently-occurring disease, and along with the raising of people's living standard and the change of living habit, this sick sickness rate obviously increases, and the age of morbidity also shifts to an earlier date to some extent.The caused atherosclerosis of hyperlipemia is to cause the main cause of coronary heart disease, hypertension and cerebrovascular disease, and the whole world approximately has 1,200 ten thousand people to die from cardiovascular diseases and apoplexy every year.So the treatment of hyperlipemia is extremely important, this has caused showing great attention to of the whole mankind.The final purpose for the treatment of hyperlipemia is to suppress arteriosclerotic further developing, thereby prevents the death being caused by cardio-cerebrovascular diseases.
Lhasa rhubarb element A (compound 1) and Lhasa rhubarb element B (compound 2) are two novel resveratrol trimers, by inventor's separation and Extraction to carry out structure definite from Rheum ripple leaf group plant plant Lhasa rhubarb (Rheum lhasaense A.J.Li et P.K.Hsiao) first.The report of inanimate object activity.Its structural formula is suc as formula shown in one, two.
The chemical constitution of formula one Lhasa rhubarb element A (compound 1)
The chemical constitution of formula two Lhasa rhubarb element B (compound 2)
Summary of the invention
The chemical structural formula (shown in one, two) of the open noval chemical compound Lhasa rhubarb element A of the present invention and Lhasa rhubarb element B.
The present invention discloses the trimeric a kind of medical usage of these two resveratrols, for the preparation of the purposes of blood fat reducing associated biomolecule preparation.
Lhasa rhubarb element A and Lhasa rhubarb element B all can significantly reduce the serum cholesterol level of hyperlipemia in mice, and Lhasa rhubarb element B can also obviously reduce the liver TG content of animal pattern; Lhasa rhubarb element A is suitable with Lhasa rhubarb element B effect for reducing fat intensity.
The purposes of the Lhasa rhubarb extract that the present invention further provides the present invention in medicine preparation.
According to conventional preparation process, the present invention's compound can be prepared into any pharmaceutical preparation that is applicable to clinical practice.As tablet, capsule, pill, powder, unguentum, dispersant, granule, injectable powder, aqueous injection etc.
Equally, the present invention's compound also can be combined with other active component the preparation that uses formation new.Obviously, these preparations that contain effective site of the present invention are within the scope of claim of the present invention.
Beneficial effect of the present invention: the present invention's noval chemical compound Lhasa rhubarb element A and Lhasa rhubarb element B have significant effect for reducing blood fat; Lhasa rhubarb element B may also have certain lipotropic effect, aspect the medicine as preparation control hyperlipidemia, is having been widely used.
Brief description of the drawings:
Fig. 1 is Electrospray Mass Spectrometry (ESI-MS) spectrogram of Lhasa rhubarb element A of the present invention.
Fig. 2 be Lhasa rhubarb of the present invention element A proton nmr spectra ( 1h NMR) spectrogram.
Fig. 3 be Lhasa rhubarb of the present invention element A undistorted polarization transfer technology carbon-13 nmr spectra ( 13cNMR) spectrogram.
Fig. 4 is relevant carbon-13 nmr spectra (HMBC) spectrogram of heteronuclear multikey of Lhasa rhubarb element A of the present invention.
Fig. 5 is Electrospray Mass Spectrometry (ESI-MS) spectrogram of Lhasa rhubarb element B of the present invention.
Fig. 6 be Lhasa rhubarb of the present invention element B proton nmr spectra ( 1h NMR) spectrogram.
Fig. 7 be Lhasa rhubarb of the present invention element B undistorted polarization transfer technology carbon-13 nmr spectra ( 13cNMR) spectrogram.
Fig. 8 is relevant carbon-13 nmr spectra (HMBC) spectrogram of heteronuclear multikey of Lhasa rhubarb element B of the present invention.
Detailed description of the invention
Below in conjunction with the drawings and specific embodiments, technical scheme of the present invention is described in more detail.
Embodiment 1: the structure elucidation of Lhasa rhubarb element A and Lhasa rhubarb element B
Lhasa rhubarb element A is pale yellow powder, and its optical rotation is: the molecular ion peak m/z679[M-H that the ESI-MS of (C=0.0056, MeOH) (-) provides] +(HR-ESI-MS:680.9614, calculated for C 42h 32o 9, see accompanying drawing 1) and determine that molecular formula is C 42h 32o 9, degree of unsaturation is 27.Analysis of compounds 1h NMR and 1h- 1h COSY spectrum: fragrant hydrogen signal δ h7.12 (d, J=8.5Hz, 2H), δ h6.77 (d, J=8.5Hz, 2H) and δ h7.16 (d, J=8.5Hz, 2H), δ h6.75 (d, J=8.5Hz, 2H) show that molecule exists two A 2b 2system, is expressed as A 1ring and C 1ring; δ h6.10 (d, J=2.0Hz, 2H), δ h6.14 (t, J=2.0Hz, 1H) and δ h6.10 (d, J=2.0Hz, 2H), δ h6.17 (t, J=2.0Hz, 1H) show to contain in molecule two AX 2system, is expressed as A 2and C 2ring; δ h6.74 (d, J=8.0Hz, 1H), δ h7.21 (d, J=8.0Hz, 1H) and δ h6.94 (br s, 1H) show to contain an ABX system in molecule, are expressed as B 2ring; δ h5.28 (d, J=5.4Hz, 1H), δ h4.31 (d, J=5.4Hz, 1H) and δ h5.36 (d, J=8.3Hz, 1H), δ h4.36 (d, J=8.3Hz, 1H) show to contain in molecule two pairs of fatty hydrogen; δ h6.40 (d, J=12.2Hz, 1H), δ h6.46 (d, J=12.2Hz, 1H) show the alkene hydrogen that contains a pair of cis in molecule; From 13in C NMR, can find out δ c94.72, δ c94.49, δ c58.69, δ c56.69(7a, 8a, 7c, 8c) be 4 fatty carbon, other 38 are all aromatic carbon and olefinic carbon, and its chemical shift is between 100 and 170.Can find out δ from the relevant HMBC signal formula of H-C (accompanying drawing 2) h6.34(H-2b) and δ c129.8(C-7b), δ h6.46(H-8b) and δ c141.2(C-1b), δ c130.6(C-14b) there is distant relation, show stilbene be arranged as ring B 1-C7 b-C8 b-ring B 2; The carbon relevant to H-8a has δ c146.5(C-9a), δ c107.1(C-10a, 14a), δ c94.4(C-7a), δ c134.2(C-1a), δ c115.1(C-4b), δ c155.5(C-3b), 163.0(C-5b) show H-8a and encircle A 1, A 2, B 1be connected; The same carbon relevant to H-8c has δ cδ c145.4(C-9c), δ c107.7(C-10c, 14c), δ c94.7(C-7c), δ c132.9(C-1c), δ c131.7(C-11b), δ c127.4(C-10b), δ c160.4(C-12b), show H-8c and ring C 1, C 2, B 2be connected; Therefore the basic structure of compound is suc as formula shown in one, called after Lhasa rhubarb element A. 1h NMR and 13c NMR data full ownership is in table one.
The relevant signal formula of main HMBC (direction of arrow is from H to C) of formula three Lhasa rhubarb element A (compound 1) and B (compound 2)
Lhasa rhubarb element B is pale yellow powder, and its optical rotation is: the molecular ion peak m/z679[M-H that the ESI-MS of (C=0.0054, MeOH) (-) provides] +(680.9614, calculated forC 42h 32o 9) determine that molecular formula is C 42h 32o 9, degree of unsaturation is 27.Analysis of compounds 1h NMR and 1h- 1hCOSY spectrum: fragrant hydrogen signal δ h7.13 (d, J=8.5Hz, 2H), δ h6.76 (d, J=8.5Hz, 2H) and δ h7.17 (d, J=8.5Hz, 2H), δ h6.79 (d, J=8.5Hz, 2H) show that molecule exists two A 2b 2system, is expressed as A 1ring and C 1ring; δ h6.13 (d, J=1.7Hz, 2H), δ h6.16 (t, J=1.7Hz, 1H) and δ h6.15 (d, J=1.7Hz, 2H), δ h6.22 (t, J=1.7Hz, 1H) show to contain in molecule two AX 2system, is expressed as A 2and C 2ring; δ h6.84 (d, J=8.3Hz, 1H), δ h7.37 (d, J=8.3Hz, 1H) and δ h7.20 (br s, 1H) show to contain an ABX system in molecule, are expressed as B 2ring; δ h5.30 (d, J=5.4Hz, 1H), δ h4.34 (d, J=5.4Hz, 1H) and δ h5.39 (d, J=8.4Hz, 1H), 4.44 (d, J=8.4Hz, 1H) show to contain in molecule two pairs of fatty hydrogen; Above data are all similar with compound 1, but the chemical shift contrast of the alkene hydrogen of two compounds is very large, wherein δ in compound 1 h6.40 (d, J=12.2Hz, 1H), δ h6.46 (d, J=12.2Hz, 1H) are shown to be a cis-structure, and are δ in compound 2 h6.85 (d, J=16.2Hz, 1H), δ h7.02 (d, J=16.2Hz, 1H) show to contain in molecule a pair of anti-alkene hydrogen; From 13in CNMR, can find out δ c99.65, δ c94.94, δ c58.74, δ c56.64(7a, 8a, 7c, 8c) be 4 fatty carbon, other 38 are all aromatic carbon and olefinic carbon, and its chemical shift is between 100 and 170.Can find out δ from the relevant HMBC signal formula of H-C (accompanying drawing 3) h6.50(H-2b) and δ c127.4(C-7b), δ h6.50(H-8b) and δ c141.5(C-1b), δ c128.7(C-14b) there is distant relation, show stilbene be arranged as ring B 1-C7 b-C8 b-ring B 2; The carbon relevant to H-8a has δ c146.6(C-9a), δ c107.0(C-10a, 14a), δ c94.5(C-7a), δ c134.3(C-1a), δ c115.4(C-4b), δ c155.6(C-3b), δ c163.3(C-5b) show H-8a and ring A 1, A 2, B 1be connected; The same carbon relevant to H-8c has δ c145.3(C-9c), δ c107.9(C-10c, 14c), δ c94.9(C-7c), δ c132.8(C-1c), δ c132.4(C-11b), δ c124.1(C-10b), δ c160.9(C-12b), show H-8c and ring C 1, C 2, B 2be connected; The basic structure of this compound is suc as formula shown in two, called after Lhasa rhubarb element B. 1h NMR and 13c NMR data full ownership is in table one.
Table 1 Lhasa rhubarb element A and Lhasa rhubarb element B's 1h NMR, 13c NMR data
The 1H NMR of continued 1 compound 1 and compound 2,13C NMR data
Embodiment 2: the effect for reducing fat research of the effect for reducing fat research series samples of Lhasa
1 material
1.1 medicine
S 1sample, yellow powder, is the research code name of Lhasa rhubarb element A; S 2sample, yellow powder, is the research code name of Lhasa rhubarb element B.Fenofibrate, 100mg/ sheet, Yan'an Wanxiang Pharmaceutical Co., Ltd., Shanghai produces, lot number 121101.When experiment, with 0.5%CMC-Na respectively by S 1~S2 sample and positive control fenofibrate are made into the suspension of desired concn.
1.2 reagent
Triglyceride (TG, 1204101), cholesterol (TC, 1204101) test kit, Sichuan Mai Ke Science and Technology Ltd. produces; Cholesterol (13030) and natrii tauroglycocholas (20131201) biochemical reagents, Beijing extensive and profound in meaning star biochemical technology Co., Ltd produces.
1.3 animal
SPF level ICR mice; Clean level Mus mixed feed; Provided by unming Medical College's Experimental Animal Center.
1.4 instrument
TMS1024 automatic clinical chemistry analyzer, Tokyo Co., Ltd.; Centrifuge5810R type refrigerated centrifuger, German eppendoff company; BS110 type electronic analytical balance, Sai Duolisi company; Millipor ultra-pure-water treatment system, Millipor company of the U.S..
1.5 statistics
Data with represent, carry out t with Excel and check the relatively significance of group difference.
2 methods and result
Select 143 of 18~20g male mices, be divided at random 14 groups: blank group; 1 group, model (0.5%CMC-Na); 2 groups, model (2% tween 80); Fenofibrate 100mg/kg group; S 1~S 30.5,2.0g/kg group; SO~SZO0.2,1.0g/kg group; Blank and model control group is 11, and all the other each group is 10.Except Normal group is fed normal diet, all the other each treated animals are all fed high lipid food, freely ingest and drink water.During moulding each treated animal morning every day on an empty stomach according to dosage timing gastric infusion once, volume is 20ml/kg, 1 group, blank group and model gavage 0.5%CMC-Na, 2 groups, model gavages 2% tween 80, continuous 7 days.After last administration, water 12h is can't help in fasting, gets blood by eye socket, and separation of serum, by the content of kit method mensuration TC and TG.After getting blood, animal is put to death in dislocation, wins liver and weighs, and calculates liver coefficient, and takes sample 200 ± 2mg in liver with position, uses ethanol: acetone (1:1) mixes extract 2ml homogenate, measures the TG content in hepatic tissue.The results are shown in Table 2 and table 3.
High lipid food formula: 1% cholesterol, 10% Adeps Sus domestica, 0.3% sodium cholate, 88.7% normal feedstuff.
The impact (X ± SD) of table 2 series samples on hyperlipemia in mice blood lipid level
Compared with blank group: △ P<0.01; : ﹡ P<0.05 compared with model group
Experimental result shows, positive control fenofibrate, S 1and S 2two dosage groups all can obviously reduce the serum cholesterol level of hyperlipemia in mice, S 3there is obvious reduction serum TC trend.
The impact of table 3 series samples on hyperlipemia in mice liver exponential sum liver TG
Compared with blank group: △ P<0.01; Compared with model group: * P<0.05, * * P<0.01
Experimental result shows, the TG regulating liver-QI coefficient of model group animal livers obviously raises; S 2two dosage groups can obviously reduce the liver TG content of hyperlipemia in mice, and liver coefficient is had no significant effect;
3. brief summary
S 1and S 2all can significantly reduce the serum cholesterol level of hyperlipemia in mice, S 2can also obviously reduce the liver TG content of animal pattern; S 1and S 2effect for reducing fat intensity is suitable, but S 2there is the advantage of obvious reduction liver TG content; Result: S1, S2 can significantly reduce the blood lipid level of hyperlipemia in mice; S2 can also significantly reduce the liver TG of hyperlipemia in mice.Conclusion: S1, S2 have significant effect for reducing blood fat; S2 may also have certain lipotropic effect.
Embodiment 3: Lhasa rhubarb element tablet preparation
Method for making: take Lhasa rhubarb element A or B100g, be dissolved in appropriate ethanol, add 900g PVPK29/32, mix homogeneously, makes abundant dissolving; Rotary evaporation makes ethanol volatilization, cooling, dry, solidify, pulverize solidfied material, get 100 grams and mix with 50 grams of lactose, 30 grams of pregelatinized Starch, 10 grams of carboxymethyl starch sodium, cross 80 mesh sieve 2 times, mix homogeneously, taking 1% low-substituted hydroxypropyl cellulose alcoholic solution (concentration 50%) as binding agent soft material processed, crossing 40 mesh sieves granulates, 60 DEG C dry, crosses 30 mesh sieve granulate, adds 1.5 grams of Pulvis Talci mix homogeneously, tabletting, can prepare 1000, Lhasa rhubarb element A or Lhasa rhubarb element B tablet.

Claims (3)

1. Lhasa rhubarb A(structural formula 1) and B(structural formula 2) for the preparation of the application in fat biological preparation.
Structural formula 1
Structural formula 2
Described in claim 1 compound for the preparation of the purposes of blood lipid-lowering medicine.
Described in claim 1 compound for the preparation of the purposes of blood fat reducing health products.
CN201310182203.2A 2013-05-16 2013-05-16 Application of rheum lhasaense extract A and B in preparation of biological preparation for reducing blood fat Pending CN104161748A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310182203.2A CN104161748A (en) 2013-05-16 2013-05-16 Application of rheum lhasaense extract A and B in preparation of biological preparation for reducing blood fat

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310182203.2A CN104161748A (en) 2013-05-16 2013-05-16 Application of rheum lhasaense extract A and B in preparation of biological preparation for reducing blood fat

Publications (1)

Publication Number Publication Date
CN104161748A true CN104161748A (en) 2014-11-26

Family

ID=51905876

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310182203.2A Pending CN104161748A (en) 2013-05-16 2013-05-16 Application of rheum lhasaense extract A and B in preparation of biological preparation for reducing blood fat

Country Status (1)

Country Link
CN (1) CN104161748A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110624006A (en) * 2019-09-23 2019-12-31 昆明翔昊科技有限公司 A health wine containing effective components of fructus Quzhazhii
CN112830947A (en) * 2020-12-21 2021-05-25 中国医学科学院药用植物研究所 Stilbene compounds isolated from Lhasa rhubarb and their use in the treatment of nervous system diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005008572A (en) * 2003-06-19 2005-01-13 Yakult Honsha Co Ltd Lipase inhibitor
CN101244129A (en) * 2007-12-14 2008-08-20 昆明翔昊科技有限公司 Lhasa rhubarb extract, preparation method, and application in preparing preparation for treating cardiovascular and cerebrovascular diseases
CN101787061A (en) * 2010-03-02 2010-07-28 昆明翔昊科技有限公司 Application of Quzhazhigan in preparation of preparations for preventing and treating cardiac-cerebral ischemia diseases, and preparation method thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005008572A (en) * 2003-06-19 2005-01-13 Yakult Honsha Co Ltd Lipase inhibitor
CN101244129A (en) * 2007-12-14 2008-08-20 昆明翔昊科技有限公司 Lhasa rhubarb extract, preparation method, and application in preparing preparation for treating cardiovascular and cerebrovascular diseases
CN101787061A (en) * 2010-03-02 2010-07-28 昆明翔昊科技有限公司 Application of Quzhazhigan in preparation of preparations for preventing and treating cardiac-cerebral ischemia diseases, and preparation method thereof

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110624006A (en) * 2019-09-23 2019-12-31 昆明翔昊科技有限公司 A health wine containing effective components of fructus Quzhazhii
CN112830947A (en) * 2020-12-21 2021-05-25 中国医学科学院药用植物研究所 Stilbene compounds isolated from Lhasa rhubarb and their use in the treatment of nervous system diseases
CN112830947B (en) * 2020-12-21 2022-10-04 中国医学科学院药用植物研究所 Stilbene compounds isolated from Rheum lhasaense and their use in treating nervous system diseases
CN115650940A (en) * 2020-12-21 2023-01-31 中国医学科学院药用植物研究所 Compounds isolated from Lhasa rhubarb and their use in the treatment of neurological disorders
CN115650940B (en) * 2020-12-21 2024-03-29 中国医学科学院药用植物研究所 Compounds isolated from Rheum emodi and their use in the treatment of neurological disorders

Similar Documents

Publication Publication Date Title
Kong et al. Optimization of extraction flavonoids from Exocarpium Citri Grandis and evaluation its hypoglycemic and hypolipidemic activities
CN101732417B (en) Preparation method and application of ion pair mixture of macleaya cordata total alkaloid
CN102178741B (en) Guava leaf extract with function of reducing blood sugar as well as preparation method and application thereof
CN101979366B (en) Diphenylheptane compounds in zedoary and their medicinal uses
CN101591321B (en) Method for preparing 5,6,7,4&#39;-tetrahydroxyflavone
Sut et al. Ricinodendron heudelotii (Baill.) Heckel stem barks and seed extracts, a native food plant from Africa: Characterization by NMR and HPLC-DAD-ESI-MSn
CN102423343A (en) Broussonetia papyrifera leaf total flavone extract and preparation method and application thereof
Fecka et al. Fragaria× ananassa cv. Senga Sengana leaf: An agricultural waste with antiglycation potential and high content of ellagitannins, flavonols, and 2-pyrone-4, 6-dicarboxylic acid
Zhang et al. From tea to health: exploring abrus mollis for liver protection and unraveling its potential mechanisms
CN103919778A (en) Application of curcumin analog S1 containing piperidone structure in preparation of anti-inflammation drugs
Tie et al. Isolation of oligostilbenes from Iris lactea Pall. var. chinensis (Fisch.) Koidz and their anti-inflammatory activities
WO2013078983A1 (en) Sodium Piperonyl Pentadienoate and Use of the Same for Lowering Blood Lipid
CN104161748A (en) Application of rheum lhasaense extract A and B in preparation of biological preparation for reducing blood fat
CN101848922B (en) Novel mangiferin calcium salts, the method for preparation and use thereof
CN1887881A (en) Myricitrin preparing process
CN111560044B (en) A kind of 11-O-monkol oxime ether derivative and preparation method thereof
CN102875615B (en) Extraction method and application of falcate dolichos root or leaf glucoside A and total saponins of falcate dolichos root or leaf
CN107382837A (en) Beak tail Chinese lute A prime E and preparation method thereof and medical usage
CN113004299B (en) Xanthone compound in mangosteen bark for reducing postprandial blood sugar, and extraction method and application thereof
Zhang et al. Exploring the Immunomodulatory Properties of Red Onion (Allium cepa L.) Skin: Isolation, Structural Elucidation, and Bioactivity Study of Novel Onion Chalcones Targeting the A2A Adenosine Receptor
CN111700927B (en) A kind of medicine and food homologous composition with hypoglycemic effect and its preparation method and application
CN108310226A (en) It is a kind of to have effects that prevent the composition and the preparation method and application thereof of diabetes
CN103351285A (en) Diethylstilbestrol compound and application thereof in preparation of drug for treating osteoporosis and hyperlipemia
CN111821380A (en) Hypoglycemic composition and preparation method and application thereof
KR101252467B1 (en) PPARγ agonists isolated from Cleistocalyx operculatus and compositions for prevention and treatment of diabetis mellitus containing the same as an active ingredients

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20141126